|
"Because of the financial constraints and length of time ittakes to bring new drugs through clinical trials, scientists aremoving toward using existing drugs in new ways so that the processof translating the discoveries of today into the treatments oftomorrow can be accelerated," said Goutham Narla, MD, PhD,assistant professor, Department of Medicine, Institute ofTransformative Molecular Medicine, Case Western Reserve UniversitySchool of Medicine. Dr. Narla is also a medical geneticist atUniversity Hospitals Case Medical Center. "This 'movement' in science toward using existing FDA approveddrugs for new purposes in the treatment of cancer has expanded ourunderstanding of the pathways that cause the disease andsignificantly accelerates our ability to treat a greater number ofpatients. In many instances, every month makes a difference for apatient when dealing with terminal cancer," said Dr. Narla. Dr. Narla's laboratory focuses on the identification andcharacterization of the genes and pathways involved in cancermetastasis. By studying the functional role of the KLF6 tumorsuppressor gene, Dr. Narla and his team have identified newsignaling pathways regulated by this gene family thus providing newinsight into cancer diagnosis and treatment. The team's researchfound that KLF6 and FOXO1, both tumor suppressor genes, are turnedoff as cancer spreads through the body. By using a combination oftwo existing FDA drugs -- Erlotinib, a targeted cancer drug, andTrifluoperazine, a medication used to treat schizophrenia -- theteam developed an understanding of the properties that turn thesecritical genes back on, initiating tumor cells to die. Since first discovering the KLF6 gene 13 years ago as a medicalstudent at the Mount Sinai School of Medicine in the laboratory ofDr. Scott Friedman, Dr. Narla has been involved in theidentification and characterization of the KLF6 gene and its rolein cancer development and the progression of cancer. This study appears online in the Journal of Clinical Investigation . Additional support for Dr. Narla's research comes from the CaseComprehensive Cancer Center, Case Western Reserve University Schoolof Medicine, Case Western Reserve University Institute forTransformative Molecular Medicine, and the Mount Sinai School ofMedicine. Dr. Narla is also supported by an early physicianscientist career award from the Howard Hughes Medical Institute(HHMI). Recently, Dr. Narla has also been named the first HarringtonDistinguished Scholar. This inaugural award providesphysician-scientists who have potential breakthroughs with theability to tap into grant funding, as well as a peer network ofinnovators and mentors within the University Hospitals HarringtonDiscovery Institute's infrastructure to support their discoveryefforts Dr. Narla is the principal investigator leading a multidisciplinaryteam with investigators at both the Mount Sinai School of Medicineand the Case Western Reserve University School of Medicine thatincludes Jaya Sangodkar, Neil S. Dhawan, Heather Melville, Varan J.Singh, Eric Yuan, Huma Rana, Sudeh Izadmehr, Caroline Farrington,Sahar Mahzar, Suzanna Katz, Tara Albano, Pearlann Arnovitz, RachaelOkrent, Michael Ohlmeyer, David Burstein, David Zhang, KaterinaPoliti and Analisa DiFeo. I am an expert from womens-cottontights.com, while we provides the quality product, such as Womens Ankle Socks , China Mens Ankle Socks, Womens Cotton Tights,and more.
Related Articles -
Womens Ankle Socks, China Mens Ankle Socks,
|
